NYSTATIN-TRIAMCINOLONE ACETONIDE
Clinical safety rating: avoid
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
Nystatin is a polyene antifungal that binds to ergosterol in the fungal cell membrane, forming pores that cause leakage of intracellular contents and cell death. Triamcinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and reducing prostaglandin and leukotriene synthesis, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Nystatin is not significantly absorbed through intact skin or mucous membranes; systemic metabolism is negligible. Triamcinolone acetonide is metabolized primarily in the liver via CYP3A4 to 6β-hydroxytriamcinolone and other metabolites. |
| Excretion | Nystatin: negligible systemic absorption; excreted unchanged in feces (~100%). Triamcinolone acetonide: metabolized hepatically; renal excretion of metabolites (~40%) and unchanged drug (<5%); fecal excretion (~60%). |
| Half-life | Nystatin: negligible systemic half-life due to lack of absorption. Triamcinolone acetonide: terminal half-life ~2-5 hours (mean ~3.5 h) after intravascular administration; prolonged in hepatic impairment. |
| Protein binding | Nystatin: negligible binding (not absorbed). Triamcinolone acetonide: ~68% bound to albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Nystatin: not applicable (no systemic distribution). Triamcinolone acetonide: Vd ~1.2 L/kg (0.8-1.5 L/kg), indicating extensive tissue distribution. |
| Bioavailability | Nystatin: essentially 0% oral/nasal (not absorbed); topical/vaginal: minimal systemic absorption. Triamcinolone acetonide: topical: <1% systemic absorption through intact skin; intramuscular: ~100% after injection. |
| Onset of Action | Nystatin: local effects on Candida begin within 24-72 hours of topical/ vaginal/oral application. Triamcinolone acetonide: topical anti-inflammatory effects noticeable within 2-3 days; intramuscular (systemic) onset within 24 hours. |
| Duration of Action | Nystatin: clinical effect persists during continued application; no systemic duration. Triamcinolone acetonide: topical duration 2-4 weeks after cessation due to depot in skin; intramuscular effects last 2-3 weeks due to slow release from injection site. |
| Molecular Weight | Nystatin: 926.09 Da; Triamcinolone acetonide: 434.50 Da |
Apply topically to affected area twice daily for 2-4 weeks.
| Dosage form | OINTMENT |
| Renal impairment | No dosage adjustment required for topical use; systemic absorption is negligible. |
| Liver impairment | No dosage adjustment required for topical use; systemic absorption is negligible. |
| Pediatric use | Apply sparingly to affected area twice daily; use for shortest duration necessary. Not recommended for children under 2 years unless directed by physician. |
| Geriatric use | Use with caution due to increased risk of skin atrophy and systemic effects from prolonged use; apply sparingly and for shortest duration. |
| 1st trimester | Topical use is considered low risk; systemic absorption is minimal. Animal studies have not shown fetal risk, and there are no adequate human studies. Use only if clearly needed. |
| 2nd trimester | Same as first trimester; minimal systemic absorption due to topical application. No increased risk of fetal harm reported. |
| 3rd trimester | Same as first and second trimesters; use with caution near term, but no specific contraindications. |
Clinical note
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
| FDA category | Positive |
| Placental transfer | Minimal to none due to low concentration in topical products; systemic absorption after topical application is less than 1%. |
■ FDA Black Box Warning
None
| Common Effects | Hyperglycemia |
| Serious Effects |
Hypersensitivity to nystatin, triamcinolone acetonide, or any componentsFungal infections of the nails, scalp, or mouth (not indicated)Viral skin infections (e.g., herpes simplex, varicella)Untreated bacterial skin infections
| Precautions | Prolonged use may lead to topical corticosteroid side effects including skin atrophy, striae, telangiectasias, and systemic absorption with hypothalamic-pituitary-adrenal (HPA) axis suppression, especially in children, on large areas, or under occlusion, If irritation or sensitization occurs, discontinue use, Do not use in the presence of untreated bacterial, viral, or fungal infections other than candidiasis, Avoid prolonged application to the face, groin, axillae, and intertriginous areas due to increased absorption, Use caution in patients with impaired immune response |
| Food/Dietary |
Loading safety data…
| Breastfeeding |
| Topical application to the breast should be avoided to prevent infant ingestion. Limited systemic absorption; unlikely to cause adverse effects in the nursing infant. Use only on small areas and for short duration. |
| Lactation Rating | L2 (Possibly Compatible) |
| Teratogenic Risk | Animal studies with triamcinolone acetonide have shown teratogenicity; corticosteroids are associated with increased risk of cleft palate and intrauterine growth restriction. Nystatin is not absorbed systemically and is considered low risk. First trimester: avoid systemic absorption; use only if benefit outweighs risk. Second/third trimester: avoid prolonged use due to potential fetal adrenal suppression. |
| Fetal Monitoring | Monitor fetal growth via ultrasound due to potential IUGR with prolonged corticosteroid use. Assess maternal adrenal function if used extensively. Monitor infant for signs of adrenal suppression if maternal use was prolonged/high-dose. |
| Fertility Effects | No known effect of nystatin on fertility. Triamcinolone acetonide may impair fertility in animal studies via hormonal disruption; human data limited. |
| No clinically significant food interactions. |
| Clinical Pearls | Nystatin/Triamcinolone Acetonide is a fixed-dose combination antifungal and corticosteroid used for dermatophyte infections with significant inflammation. Avoid use on ocular, oral, or genital mucous membranes due to corticosteroid absorption. Use limited to 2 weeks; prolonged use risks skin atrophy, striae, and systemic steroid effects. Reassess if no improvement within 1 week. |
| Patient Advice | Apply thin layer to affected area twice daily for no more than 2 weeks. · Do not use on the face, groin, or armpits unless directed by your doctor. · Avoid covering the area with bandages or other occlusive dressings. · Wash hands before and after application unless treating hands. · Do not use for diaper rash in children under 2 years. · Report any signs of skin thinning, irritation, or worsening infection. |